Fig. 3
Validation with CCLE dataset. a, b Responses of cells with BRAF, KRAS, or NRAS mutations to treatment with AZD6244 (a) or PD-0325901 (b). Each row in the heatmap represents a gene and each column represents a cell line, with mutations in red and wildtype in yellow. 450 (a) and 451 (b) cell lines covering multiple cancer types were respectively investigated for each drug. Cell lines were ranked by drug sensitivity with a range of 0 to 6.49 (a), and 0 to 7.38 (b). c–e Responses of cells with mutant EGFR, BRAF, KRAS, or NRAS to different anticancer drugs targeting the ERK signalling pathway, measured as activity area. Statistical significance is compared to wildtype. *Adjusted p < 0.05; **adjusted p < 10−3; ***adjusted p < 10−6.